巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Anixa Biosciences

    ANIX
    2.980
    0.050
    1.65%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Anixa Biosciences - 延遲價格・最後更新於 01/07 12:14
    最高位
    3.060
    最低位
    2.930
    開市價
    --
    前收市價
    3.030
    成交量(千)
    0.33
    成交額(百萬)
    0.01
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    90.80
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    5.870 - 2.300
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Anixa Biosciences
    證券代碼
    ANIX.US
    所屬板塊
    Biotechnology
    公司業務
    Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.
    發行量
    30152319
    公司總部
    3150 Almaden Expressway, Suite 250
    公司網址
    https://www.anixa.com
    公司電話
    +1 408 708-9808

    美股三大股指小幅高開 中概股多數回調

    李進·
    美股三大股指小幅高開 中概股多數回調

    關於

    Anixa Biosciences(ANIX.US)所屬的行業板塊為Biotechnology。
    Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.
    詳細公司背景可參考: https://www.anixa.com